The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia

Neuropsychopharmacology

Volumn 20, Issue 3, 1999, Pages 201-225

  Jentsch, J David ^a   Roth, Robert H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Catecholamine; Cognition; Dopamine; Glutamate; Ketamine; Memory; Phencyclidine; Prefrontal cortex; Psychotomimetic; Schizophrenia

Indexed keywords

CLOZAPINE; DOPAMINE RECEPTOR; GLUTAMIC ACID; HALOPERIDOL; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BEHAVIOR; COGNITION; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; HUMAN; MODEL; MONKEY; MOUSE; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; REVIEW; SCHIZOPHRENIA;

ANIMALS; BRAIN CHEMISTRY; COGNITION; DISEASE MODELS, ANIMAL; DOPAMINE; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; PHENCYCLIDINE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 0032903301     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00060-8     Document Type: Review

References (262)

1. Adams B., Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci. 18:1998;5545-5554.
2. Adler L.E., Hoffer L.D., Wiser A., Fredman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiat. 150:1993;1856-1861.
3. Aguado L., San Antonio A., Perez L., del Valle R., Gomez J. Effects of the NMDA receptor antagonist ketamine on flavor memory. Conditioned aversion, latent inhibition, and habituation of neophobia Behav Neural Biol. 61:1994;271-281.
4. Akbarian S., Kim J.J., Potkin S.G., Hagman J.O., Tafazzoli A., Bunney W.E. Jr., Jones E.G. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons of prefrontal cortex of schizophrenics. Arch Gen Psychiat. 52:1995;258-266.
5. Akil M., Lewis D.A. The catecholaminergic innervation of the human entorhinal cortex. Alterations in schizophrenia Soc Neurosci Abstr. 21:1995;238.
6. Akil M., Lewis D.A. Reduced dopamine innervation of the prefrontal cortex in schizophrenia. Soc Neurosci Abstr. 22:1996;1679.
7. Allen R.M., Young S.J. Phencyclidine-induced psychosis. Am J Psychiat. 135:1978;1081-1084.
8. American Psychiatric Association (1989): Treatments of Psychiatric Disorders; A Task Force Report of the American Psychiatric Association, vol 2. Washington, DC, American Psychiatric Association.
9. Andreasen N.C., Rezai K., Alliger R.et al. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Arch Gen Psychiat. 49:1992;943-958.
10. Angrist B.M., Gershon S. The phenomenology of experimentally induced amphetamine psychosis. Preliminary observations Biol Psychiat. 2:1970;95-107.
11. Angrist B., Peselow E., Rubenstein M., Corwin J., Rotrosen J. Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacol. 78:1982;128-130.
12. Aretha C.W., Sinha A., Galloway M.P. Dopamine D3-preferring ligands act as synthesis modulating autoreceptors. J Pharmacol Exp Ther. 274:1995;609-613.
13. Arnsten A.F.T., Goldman-Rakic P.S. α-2 adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science. 230:1985;1273-1276.
14. 1-receptor mechanism in the cognitive performance of young adult and aged monkeys. Psychopharmacology. 116:1994;143-151.
15. Arnsten A.F.T., Jentsch J.D. The α-1 agonist, cirazoline, impairs spatial working memory performance in aged monkeys. Pharmacol Biochem Behav. 58:1997;55-59.
16. Arnt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 18:1998;63-101.
17. Arvanov V.L., Wang W.Y. Clozapine, but not haloperidol or raclopride, prevents the functional hyperactivity of NMDA receptors in rat cortical neurons induced by subchronic administration of phencyclidine. Soc Neurosci Abstr. 24:1998;1827.
18. Ashby Jr. CR, Wang RY (1996): Pharmacological actions of the atypical antipsychotic drug clozapine: A review. Synapse 24:349-394.
19. Bakshi V.P., Swedlow N.R., Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther. 271:1994;787-794.
20. Bakshi V.P., Geyer M.A. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic drug olanzapine. Psychopharmacology. 122:1995;198-201.
21. Bartha R., Williamson P.C., Drost D.J.et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiat. 54:1997;959-965.
22. Benes F.M., McSparren J., Bird E.D., San Giovanni J.P., Vincent S.L. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiat. 48:1991;996-1001.
23. 1- and D5-dopamine receptors in primate brain. J Neurosci. 15:1995;7821-7836.
24. Bertolino A., Saunders R.C., Mattay V.S., Bachevalier J., Frank J.A., Weinberger D.R. Altered development of prefrontal neurons in rhesus monkeys with neonatal mesial temporo-limbic lesions. A proton magnetic resonance spectroscopic imaging study Cereb Cortex. 7:1997;740-748.
25. Bowers M.B. Jr., Hoffman F.J. Homovanillic acid in rat caudate and prefrontal cortex following phencyclidine and amphetamine. Psychopharmacology. 84:1984;137-138.
26. Bowers M.B. Jr., Mazure C.M., Nelson J.C., Jatlow P.I. Psychotogenic drug use and neuroleptic response. Schizophr Bull. 16:1990;81-85.
27. Boyce S., Rupniak N.M.J., Steventon M.J., Cook G., Iversen S.D. Psychomotor activity and cognitive disruption attributable to NMDA, but not sigma, interactions in primates. Behav Brain Res. 42:1991;115-121.
28. Braff D.L., Grillon C., Geyer M.A. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiat. 49:1992;206-215.
29. Breier A., Buchanan R.W., Waltrip R.W., Listwak S., Holmes C., Goldstein D.S. The effect of clozapine on plasma norepinephrine. Relationship to clinical efficacy Neuropsychopharmacology. 10:1994;1-7.
30. Breier A., Malhotra A.K., Pinals D.A., Weisenfeld N.I., Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry. 154:1997;805-811. a.
31. Breier A., Su T.P., Saunders R.C., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations. Evidence from a novel positron emission tomography method Proc Natl Acad Sci USA. 94:1997;2569-2574. b.
32. Breier A., Elman I., Goldstein D.S. Norepinephrine and schizophrenia. A new hypothesis for antipsychotic drug action Adv Pharmacol. 42:1998;785-788.
33. Brown R.M., Goldman P.S. Catecholamines in neocortex of rhesus monkeys. Regional distribution and ontogenetic development Brain Res. 124:1977;576-580.
34. Brozoski T.J., Brown R.M., Rosvold H.E., Goldman P.S. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science. 205:1979;929-931.
35. Bubser M., Schmidt W.J. 6-OHDA lesions of the rat prefrontal cortex increases locomotor activity, impairs acquisition of delayed alternation tasks, but does not affect uninterrupted tasks in the radial maze. Behav Brain Res. 37:1990;157-168.
36. Bunney B.G., Bunney W.E. Jr., Carlsson A. Schizophrenia and glutamate. Bloom F.E., Kupfer D.J. Psychopharmacology, The Fourth Generation of Progress. 1994;1205-1214 Raven Press, New York.
37. Carlsson A., Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol. 20:1963;140-144.
38. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1:1988;179-186.
39. Carlsson M., Carlsson A. The NMDA receptor antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm. 75:1989;221-226.
40. Carter C.S., Barch D., Cohen J.D., Braver T.S. CNS catecholamines and cognitive dysfunction in schizophrenia. Schizophr Res. 24:1997;211.
41. Castellani S., Giannini A.J., Adams P.M. Physostigmine and haloperidol treatment of acute phencyclidine intoxication. Am J Psychiat. 139:1982;508-510.
42. Cohen B.D., Rosenbaum G., Luby E.D., Gottlieb J.S. Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Simulation of schizophrenic performance with phencyclidine hydrochloride (Sernyl), lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium. II. Symbolic and sequential thinking Arch Gen Psychiat. 6:1962;395-401.
43. Corso T.D., Sesma M.A., Tenkova T.I.et al. Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Res. 752:1997;1-14.
44. Cosgrove J., Newell T.G. Recovery of neuropsychological functions during reduction in use of phencyclidine. J Clin Psychol. 47:1991;159-169.
45. Courtney S.M., Petit L., Maisog J.M., Ungerleider L.G., Haxby J.V. An area specialized for spatial working memory in human frontal cortex. Science. 279:1998;1347-1351.
46. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 192:1976;481-483.
47. Daniel D.G., Berman K.F., Weinberger D.R. The effect of apomorphine on regional cerebral blood flow in schizophrenia. J Neuropsychiat. 1:1989;377-384.
48. Daniel D.G., Weinberger D.R., Jones D.W.et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci. 11:1991;1907-1917.
49. Davies B.M., Beech H.R. The effect of 1-arylcyclohexylamine (Sernyl) on twelve normal volunteers. J Mental Sci. 106:1960;912-924.
50. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia. A review and reconceptualization Am J Psychiat. 148:1991;1474-1486.
51. Day J., Fibiger H.C. Dopaminergic regulation of cortical acetylcholine release. Synapse. 12:1992;281-286.
52. Day J., Fibiger H.C. Dopaminergic regulation of cortical acetylcholine release. Effects of dopamine receptor agonists Neurosci. 54:1993;643-648.
53. Dazzi L., Jentsch J.D., Roth R.H. Acute phencyclidine exposure increases acetylcholine and catecholamine release in rat prefrontal cortex in vivo. Modulation by S-(-)HA966 and clonidine Soc Neurosci Abstr. 24:1998;744.
54. Deutch A.Y., Tam S.Y., Freeman A.S., Bowers Jr M.B., Roth R.H. Mesolimbic and mesocortical dopamine activation induced by phencyclidine. Contrasting response to striatal response Eur J Pharmacol. 134:1987;257-264.
55. Deutch A.Y., Clark W.A., Roth R.H. Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Res. 521:1990;311-315.
56. Deutch A.Y., Roth R.H. Determinants of stress-induced activation of the prefrontal cortical dopamine system. Prog Brain Res. 85:1990;367-403.
57. Deutch A.Y. The regulation of subcortical dopamine systems by the prefrontal cortex. Interactions of central dopamine systems and the pathogenesis of schizophrenia J Neural Transm [Gen Sect]. 36:1992;61-89.
58. Diamond A., Goldman-Rakic P.S. Evidence for involvement on prefrontal cortex in cognitive changes during the first year of life. Comparison of performance of human infants and rhesus monkeys on a detour task with transparent barrier Soc Neurosci Abstr. 11:1985;832.
59. Diamond A (1988): Differences between adult and infant cognition: Is the crucial variable presence or absence of language? In Weiskrantz L (ed), Thought Without Language. New York, Oxford University Press, pp 337-370.
60. Diamond A., Zola-Morgan S., Squire L.R. Successful performance by monkeys with lesions of the hippocampal formation on A-B and object retrieval, two tasks that mark developmental changes in human infants. Behav Neurosci. 103:1989;526-537.
61. Diamond A. Evidence for the importance of dopamine for prefrontal cortex functions early in life. Phil Tran Roy Soc Lond, B. 351:1996;1483-1494.
62. Dias R., Robbins T.W., Roberts A.C. Dissociation in prefrontal cortex of affective and attentional shifts. Nature. 380:1996;69-72. a.
63. Dias R., Robbins T.W., Roberts A.C. Primate analog of the Wisconsin Card Sorting Test. Effects of excitotoxic lesions of the prefrontal cortex in the marmoset Behav Neurosci. 110:1996;872-886. b.
64. Dias R., Robbins T.W., Roberts A.C. Dissociable forms of inhibitory control within prefrontal cortex with an analog of the Wisconsin Card Sort test - Restriction to novel situations and independence from on-line processing. J Neurosci. 17:1997;9285-9297.
65. 3-receptor in the rat brain. Neuroscience. 65:1995;731-745.
66. Dickerson F., Boronow J.J., Ringel N., Parente F. Neurocognitive deficits and social functioning in outpatients with schizophrenia. Schizophr Res. 21:1996;75-83.
67. Doherty J.D., Simonovic M., So R., Meltzer H.Y. The effect of phencyclidine on dopamine synthesis and metabolism in rat striatum. Eur J Pharmacol. 65:1980;139-149.
68. Dolan R.J., Fletcher P., Frith C.D., Friston K.J., Frackowiak R.S.J., Grasby P.M. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature. 378:1995;180-182.
69. D'Souza DC, Belger A, Zimmerman L, Adams S, Gil R, Sernyak M, Krystal J (1997): Cannabinoid sensitivity in schizophenia: Dose-response of tetrahydrocannabinol effects in schizophrenics and healthy controls. (Abstr) Am Coll Neuropsychopharmacol 36:286.
70. El-Khodor B.F., Boksa P. Long-term reciprocal changes in dopamine levels in prefrontal cortex versus nucleus accumbens in rats born by caesarean section compared to vaginal birth. Exp Neurol. 145:1997;118-129.
71. Ellison G., Switzer R.C. Dissimilar patterns of degeneration in brain following four different addictive stimulants. Neuroreport. 5:1993;17-20.
72. Ellison G. Competitive and noncompetitive NMDA receptor antagonists induce similar limbic degeneration. Neuroreport. 5:1994;2688-2692.
73. Ellison G. The N-methyl-D-aspartate antagonists phencyclidine, ketamine, and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res Rev. 20:1995;250-267.
74. Everitt B.J., Rogers R.D., Baldacchino A., Johnson A.J., Swainson R., London M., Deakin G.W.F., Robbins T.W., Sahakian B.J. Altered decision-making following frontal lesions. A comparison with amphetamine and opiate-abusers Soc Neurosci Abstr. 23:1997;495.
75. Farber N.B., Price M.T., Labruyere J., Nemnich J., St Peter H., Wozniak D.F., Olney J.W. Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Biol Psychiat. 34:1993;119-121.
76. Farber N.B., Foster J., Duhan N.L., Olney J.W. α-2 adrenergic agonists prevent MK801 neurotoxicity. Neuropsychopharmacology. 12:1995;347-349.
77. Farber N.B., Foster J., Duhan N.L., Olney J.W. Olanzapine and fluperapine mimic clozapine in preventing MK801 neurotoxicity. Schizophr Res. 21:1996;33-37.
78. Fey E.T. The performance of young schizophrenics and young normals on the Wisconsin Card Sorting Test. J Consult Psychol. 15:1951;311-319.
79. Fraser C.M., Fisher A., Cooke M.J., Thompson I.D., Stone T.W. Purine modulation of dizocilpine effects on spontaneous alternation. Psychopharmacology. 130:1997;334-342.
80. Frederick D.L., Gillam M.P., Allen R.R., Paule M.G. Acute behavioral effects of phencyclidine on rhesus monkey performance in an operant test battery. Pharmacol Biochem Behav. 52:1995;789-797.
81. Freed W.J., Weinberger D.R., Bing L.A., Wyatt R.J. Neuropharmacological studies of phencyclidine (PCP)-induced behavioral stimulation in mice. Psychopharmacology. 71:1980;291-297.
82. Freedman A.S., Bunney B.S. The effects of phencyclidine and N-allyl-normetazocine on midbrain dopamine neuronal activity. Eur J Pharmacol. 104:1984;287-293.
83. Freedman M., Oscar-Berman M. Bilateral frontal lobe disease and selective delayed response deficits in humans. Behav Neurosci. 100:1986;337-342.
84. French E.D. Phencyclidine and the midbrain dopamine system. Electrophysiology and behavior Neurotoxicol Teratol. 16:1994;355-362.
85. Fuster J.M. The Prefrontal Cortex. Anatomy, Physiology, and Neuropsychology of the Frontal Lobe 2:1997;Lippincott-Raven, Philadelphia.
86. Gao X.M., Shirakawa O., Du F., Tamminga C.A. Delayed regional metabolic actions of phencyclidine. Eur J Pharmacol. 241:1993;7-15.
87. Gao X.M., Tamminga C.A. Phencyclidine produces changes in NMDA and kainate receptor binding in rat hippocampus over a 48-hour time course. Synapse. 23:1996;274-279.
88. Geyer M.A., Segal D.S., Greenberg B.D. Increased startle responding in rats treated with phencyclidine. Neurobehav Toxicol Teratol. 6:1984;1-4.
89. Geyer M.A., Braff D.L. Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr Bull. 13:1987;643-668.
90. Geyer M.A., Markou A. Animal models of psychiatric disorders. Bloom F.E., Kupfer D.J. Psychopharmacology, The Fourth Generation of Progress. 1994;787-798 Raven Press, New York.
91. Giannini A.J., Eighan M.S., Loiselle R.H., Giannini M.C. Comparison of haloperidol and chlorpromazine in the treatment of phencyclidine psychosis. J Clin Pharmacol. 24:1984;202-204.
92. Giovannini M.G., Mutolo D., Bianchi L., Michelassi A., Pepeu G. NMDA receptor antagonists decreases GABA outflow from the septum and increase acetylcholine outflow from the hippocampus. A microdialysis study J Neurosci. 15:1994;1358-1365.
93. Glazer W.M., Charney D.S., Heninger G.R. Noradrenergic function in schizophrenia. Arch Gen Psychiatry. 44:1987;898-904.
94. Goff D.C., Henderson D.C., Amico E. Cigarette smoking in schizophrenia. Relationship to psychopathology and medication side-effects Am J Psychiat. 149:1992;1189-1194.
95. Goldberg T.E., Bigelow L.B., Weinberger D.R., Daniel D.G., Kleinman J.E. Cognitive and behavioral effects of coadministration of dextro-amphetamine and haloperidol in schizophrenia. Am J Psychiat. 148:1991;78-84.
96. Goldberg T.E., Gold J.M. Neurocognitive deficits in schizophrenia. Hirsch S.R., Weinberger D.R. Schizophrenia. 1995;146-162 Blackwell, London.
97. Goldman P.S., Rosvold H.E. Localization of function within the dorsolateral prefrontal cortex of the rhesus monkey. Exp Neurol. 27:1970;291-304.
98. Goldman P.S., Rosvold H.E., Vest B., Galkin T.W. Analysis of the delayed-alternation deficit produced by dorsolateral prefrontal lesions in the rhesus monkey. J Comp Physiol Psychol. 77:1971;212-220.
99. Goldman-Rakic PS (1987): Circuitry of the frontal cortex and the regulation of behavior by representational knowledge. In Plum F, Mountcastle VM (eds), Handbook of Physiology, the Nervous System, vol 5. Bethesda, Maryland, American Physiological Society, pp 373-417.
100. Goldman-Rakic P.S. Prefrontal cortical dysfunction in schizophrenia. Relevance of working memory Carroll B.J., Barrett J.E. Psychopathology and the Brain. 1991;1-23 Raven, New York.
101. Goldman-Rakic PS, Bergson C, Mrzljak L, Williams GV (1996): Dopamine receptors and cognitive function in nonhuman primates. In Neve KA, Neve RL (eds), The Dopamine Receptors. Tuscon: Humana Press, pp 499-522.
102. Goldman-Rakic P.S., Selemon L.D. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull. 23:1997;437-458.
103. Gorelick D.A., Balster R.L. Phencyclidine (PCP). Bloom F.E., Kupfer D.J. Psychopharmacology, The Fourth Generation of Progress. 1994;1767-1776 Raven Press, New York.
104. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity. A hypothesis for the etiology of schizophrenia Neuroscience. 41:1991;1-24.
105. Grace A.A., O'Donnell P., Moore H. The modulation of corticoaccumbens transmission by limbic afferents and dopamine. A model for the pathophysiology of schizophrenia Adv Pharmacol. 42:1998;721-724.
106. Grace AA, Moore H (1998): Regulation of information flow in the nucleus accumbens: A model for the pathophysiology of schizophrenia. In Lenzenweger et al. (eds), The Pathogenesis of Schizophrenia: An Experimental Psychopathology Perspective. Washington, DC, American Psychological Association, pp 123-160.
107. Grenhoff J., Svensson T.H. Clonidine modulates dopamine cell firing in rat ventral tegmental area. Eur J Pharmacol. 165:1989;11-18.
108. Grenhoff J., Svensson T.H. Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area. Eur J Pharmacol. 233:1993;79-84.
109. Grotta J., Clark W., Coull B., Pettigrew L.C., Mackay B., Goldstein L.B., Meissner I., Murphy D., LaRue L. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Stroke. 26:1995;602-605.
110. Grunze H.C.R., Rainnie D.G., Hasselmo M.E., Barkai E., Hearn E.F., McCarley R.W., Greene R.W. NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci. 16:1994;2034-2043.
111. Grunze H.C.R., Rujescu-Balcu D., Moller H.J., Rainnie D., McCarley R.W., Greene R.W. Chronic, in vivo administration of low dose MK-801 alters CA1 local circuit inhibition in vitro. Soc Neurosci Abstr. 23:1997;2309.
112. Heale V., Harley C. MK-801 and AP-5 impair acquisition, but not retention, of the Morris milk maze. Pharmacol Biochem Behav. 36:1990;145-149.
113. Healy D.J., Meador-Woodruff J.H. Differential regulation, by MK-801, of dopamine receptor gene expression in rat nigrostriatal and mesocorticolimbic systems. Brain Res. 708:1996;38-44. a.
114. Healy D.J., Meador-Woodruff J.H. Dopamine receptor gene expression in hippocampus is differentially regulated by the NMDA receptor antagonist MK-801. Eur J Pharmacol. 306:1996;257-264. b.
115. Healy D.J., Haroutunian V., Powchik P., Davidson M., Davis K.L., Watson S.J., Meador-Woodruff J.H. AMPA receptor binding and subunit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics. Neuropsychopharmacology. in press:1998.
116. Hertel P., Mathe J.M., Nomikos G.G., Iurlo M., Mathe A.A., Svensson T.H. Effects of d-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and medial prefrontal cortex of the rat. Behav Brain Res. 72:1996;103-114.
117. Hertel P., Nomikos G.G., Schilstrom B., Arborelius L., Svensson T.H. Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex. Role of α-2 adrenoceptor antagonism Neuropsychopharmacology. 17:1997;44-55.
118. Hertzman M., Reba R.C., Kotlyarove E.V. Single photon emission computerized tomography in phencyclidine and related drug abuse. Am J Psychiat. 147:1990;255-256.
119. Hoehn-Saric R., McLeod D.R., Glowa J.R. The effects of NMDA receptor blockade on the acquisition of a conditioned emotional response. Biol Psychiat. 30:1991;170-176.
120. Hondo H., Yonezawa Y., Nakahara T., Hirano M., Uchimura H., Tashiro N. Effect of phencyclidine on dopamine release in the prefrontal cortex. An in vivo microdialysis study Brain Res. 633:1994;337-342.
121. Hsu L.L., Smith R.C., Rolsten C., Leelavathi D.E. Effects of acute and chronic phencyclidine on neurotransmitter enzymes in rat brain. Biochem Pharmacol. 29:1980;2524-2526.
122. Hudzik T.J., Wenger G.R. Effects of drugs of abuse and cholinergic agents on delayed matching-to-sample responding in squirrel monkey. J Pharmacol Exp Ther. 265:1993;120-127.
123. Hutson P.H., Hogg J.E. Effects of and interactions between antagonists for different sites on the NMDA receptor complex on hippocampal and striatal acetylcholine efflux in vivo. Eur J Pharmacol. 295:1996;45-52.
124. Ingvar D.H., Franzen G. Distribution of cerebral activity in chronic schizophrenia. Lancet. 2:1974;1484-1486.
125. Itil T., Keskiner A., Kiremitci N., Holden J.M.C. Effect of phencyclidine in chronic schizophrenics. Can J Psychiat. 12:1967;209-212.
126. Iversen S.D., Mishkin M. Perseverative intereference in monkeys following selective lesions of the inferior prefrontal convexity. Exp Brain Res. 11:1970;376-386.
127. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiat. 148:1991;1301-1308.
128. Jentsch J.D., Elsworth J.D., Redmond D.E. Jr., Roth R.H. Phencyclidine increases forebrain monoamine metabolism in rats and monkeys. Modulation by the isomers of HA966 J Neurosci. 17:1997;1769-1776. a.
129. Jentsch J.D., Tran A., Le D., Youngren K.D., Roth R.H. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology. 17:1997;92-99. b.
130. Jentsch J.D., Redmond D.E. Jr., Elsworth J.D., Taylor J.R., Youngren K.D., Roth R.H. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science. 277:1997;953-955. c.
131. 9-Tetrahydrocannabinol increases prefrontal cortical catecholaminergic turnover and impairs spatial working memory in the rat. Blockade of dopaminergic effects by HA966 Neuropsychopharmacology. 16:1997;426-432. d.
132. Jentsch J.D., Elsworth J.D., Taylor J.R., Redmond D.E. Jr., Roth R.H. Dysregulation of mesoprefrontal dopamine neurons induced by acute and repeated phencyclidine administration in the nonhuman primate. Implications for schizophrenia Adv Pharmacol. 42:1998;810-814. a.
133. Jentsch J.D., Wise A., Katz Z., Roth R.H. α-Noradrenergic modulation of the phencyclidine- and Δ9-tetrahydrocannabinol-induced increased in dopamine utilization in rat prefrontal cortex. Synapse. 28:1998;21-26. b.
134. Jentsch J.D., Taylor J.R., Roth R.H. Subchronic phencyclidine administration increases mesolimbic dopamine system responsivity and augments stress- and amphetamine-induced hyperlocomotion. Neuropsychopharmacology. 19:1998;105-113. c.
135. Jentsch J.D., Tran A., Taylor J.R., Roth R.H. Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system. Behavioral and neurochemical evidence Psychopharmacology. 138:1998;89-95. d.
136. Jentsch J.D., Taylor J.R., Elsworth J.D., Redmond D.E. Jr., Roth R.H. Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure. Involvement in frontostriatal cognitive deficits Neurosci. in press:1998;. e.
137. Jentsch J.D., Dazzi L., Roth R.H. Subchronic phencyclidine exposure reduces basal dopamine efflux and augments the cholinergic and catecholaminergic response to clozapine. Soc Neurosci Abstr. 24:1998;744. f.
138. Jentsch J.D., Taylor J.R., Redmond D.E. Jr., Elsworth J.D., Youngren K.D., Roth R.H. Reversal of phencyclidine-induced cognitive deficits in monkeys by a selective dopamine D4 receptor antagonist. Psychopharmacol. in press:1998;. g.
139. Jones K.W., Bauerle L.M., DeNoble V.J. Differential effects of sigma and phencyclidine receptor ligands on learning. Eur J Pharmacol. 179:1990;97-102.
140. Jones G.H., Marsden C.A., Robbins T.W. Increased sensitivity to amphetamine and reward-related stimuli following social isolation in rats. Possible disruption of dopamine-dependent mechanisms of the nucleus accumbens Psychopharmacology. 102:1990;364-372.
141. Kane J., Honigfeld G., Singer J., Meltzer H.Y., Group C.C. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine Arch Gen Psychiat. 45:1988;789-796.
142. Kesner R.P., Davis M. Phencyclidine disrupts acquisition and retention performance within a spatial continuous recognition memory task. Pharmacol Biochem Behav. 44:1993;419-424.
143. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis of schizophrenia. Neurosci Lett. 20:1980;379-382.
144. Knable M.B., Weinberger D.R. Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol. 11:1997;123-131.
145. Kolb B. Functions of prefrontal cortex in the rat. Brain Res Rev. 8:1984;65-98.
146. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B. Jr., Charney D.S. Subanesthetic effects of the noncompetitive NMDA receptor antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendrocrine responses Arch Gen Psychiat. 51:1994;199-214.
147. Lahti A.C., Koffel B., Laporte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1994;9-19.
148. Lahti A.C., Holcomb H.H., Medoff D.R., Tamminga C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport. 6:1995;869-872.
149. Lahti A.C., Weiler M.A., Corey P.K., Lahti R.A., Carlsson A., Tamminga C.A. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-N-propylpiperidine (Preclamol) in schizophrenia. Biol Psychiat. 43:1998;2-11.
150. Lannes B., Micheletti G., Warter J.M., Kempf E., DiScala G. Behavioral, pharmacological, and biochemical effects of acute and chronic administration of ketamine in the rat. Neurosci Lett. 128:1991;177-181.
151. Laruelle M., Abi-Dargham A., Van Dyck C., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., Innis R.B. Single photon emission computerized tomography imaging of amphetaine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA. 93:1996;9235-9240.
152. Levin E.D., Wilson W., Rose J.E., McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacol. 15:1996;429-436.
153. Lewis D.A., Anderson S.A. The functional architecture of the prefrontal cortex and schizophrenia. Psychol Med. 25:1995;887-894.
154. 2-dopamine receptors in the primate cerebral cortex. Proc Natl Acad Sci USA. 91:1994;4353-4356.
155. Lieberman J.A., Sheitman B.B., Kinon B.J. Neurochemical sensitization in the pathophysiology of schizophrenia. Deficits and dysfunction in neuronal regulation and plasticity Neuropsychopharmacology. 17:1997;205-229.
156. Lindefors N., Barati S., O'Connor W.T. Differential effects of single and repeated ketamine administration on dopamine, serotonin, and GABA transmission in rat prefrontal cortex. Brain Res. 759:1997;202-212.
157. Lipska B.K., Jaskiw G.E., Weinberger D.R. Postpubertal emergence of hyper-responsiveness to stress and to amphetamine after neonatal damage. A potential animal model of schizophrenia Neuropsychopharmacology. 9:1993;67-75.
158. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelly R. Study of a new schizophrenic-like drug. Sernyl Arch Neurol Psychiat. 81:1959;363-369.
159. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., Breier A. NMDA receptor function and human cognition. The effects of ketamine in healthy volunteers Neuropsychopharmacology. 14:1996;301-307.
160. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 17:1997;141-149. a.
161. Malhotra A.K., Adler C.M., Kennison S.D., Elman I., Pickar D., Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis. A study with ketamine Biol Psychiat. 42:1997;664-668. b.
162. Martin P., Carlsson M.L., Hjorth S. Systemic PCP treatment elevates brain extracellular 5-HT. A microdialysis study in awake rats NeuroReport. in press:1998.
163. Mathe J.M., Nomikos G.G., Hildebrand B.E., Hertel P., Svensson T.H. Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur J Pharmacol. 309:1996;1-11.
164. Mathe J.M., Nomikos G.G., Schilstrom B., Svensson T.H. Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK-801)-induced hyperlocomotion and dopamine release in the nucleus accumbens. J Neurosci Res. 51:1998;583-592.
165. Maurel-Remy S., Bervoets K., Millan M.J. Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2a receptors. Eur J Pharmacol. 280:1995;9-11.
166. McCullough L.D., Salamone J.D. Increases in extracellular dopamine levels and locomotor activity after direct infusion of phencyclidine into nucleus accumbens. Brain Res. 577:1992;1-9.
167. Meador-Woodruff J.H., Haroutunian V., Powchick P., Davidson M., David K.L., Watson S.J. Abnormal NMDA receptor expression in schizophrenic prefrontal cortex. Abstr Am Coll Neuropsychopharmacol. 36:1997;167.
168. Melnick S.M., Walsh J.S., Clark J.P., Ettenberg A. Can the behavioral sensitization to repeated phencyclidine be accounted for by tolerance to the drug's ataxic effects? Soc Neurosci Abstr. 23:1997;1093.
169. Meltzer H.Y. The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. J clin Psychopharmacol. 15:1995;2-3.
170. Miller R.E., Levine J.M., Mirsky I.A. Effects of psychoactive drugs on nonverbal communication and group social behavior of monkeys. J Pers Soc Psychol. 28:1973;396-405.
171. Milner B. Effects of different brain lesions on card sorting. Arch Neurol. 9:1963;100-110.
172. Milner B. Some cognitive effects of frontal lobe lesions in man. Phil Trans R Soc Lond B. 286:1982;211-226.
173. Moerschbaecher J.M., Thompson D.M. Effects of phencyclidine, pentobarbital, and d-amphetamine on the acquisition and performance of conditional discriminations in monkeys. Pharmacol Biochem Behav. 13:1980;887-894.
174. Moghaddam B., Adams B. Reversal of phencyclidine effects by a group II metabotripic glutamate receptor agonist. Science. 281:1998;1349-1352.
175. Moghaddam B., Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat. An in vivo microdialysis study J Neurochem. 54:1990;1755-1760.
176. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine. A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex J Neurosci. 17:1997;2921-2927.
177. Moll L., Kuypers H.G.J.M. Premotor cortical ablations in monkeys. Contralateral changes in visually- guided reaching behavior Science. 198:1977;317-319.
178. Moore H., Grace A.A. Interactions between amygdala and prefrontal cortical afferents to the nucleus accumbens and their modulation by dopamine receptor activation. Soc Neurosci Abstr. 22:1996;1088.
179. Moore H., Grace A.A. Anatomical changes in limbic structures produced by methylazoxymethanol acetate (MAM) during brain development are associated with changes in physiological interactions among afferents to the nucleus accumbens. Soc Neurosci Abstr. 23:1997;2378.
180. Moore H., Fadel J., Sarter M., Bruno J.P. Role of accumbens and cortical dopamine receptors in the regulation of cortical acetylcholine release. Neuroscience. in press:1998.
181. 4-receptor to GABAergic neurons of the primate brain. Nature. 381:1996;245-248.
182. Murphy B.L., Arnsten A.F.T., Goldman-Rakic P.S., Roth R.H. Increased dopamine turnover in prefrontal cortex impairs spatial working memory in rats and monkeys. Proc Natl Acad Sci USA. 93:1996;1325-1329. a.
183. Murphy B.L., Arnsten A.F.T., Jentsch J.D., Roth R.H. Dopamine and spatial working memory in rats and monkeys. Pharmacological reversal of stress-induced impairment J Neurosci. 16:1996;7768-7775. b.
184. Murray T.F., Cheney D.L. The effect of phencyclidine on the turnover rate of acetylcholine in various regions of rat brain. J Pharmacol Exp Ther. 217:1981;733-737.
185. Murray T.K., Ridley R.M. The effect of dizocilpine (MK-801) on conditional discrimination learning in the rat. Behav Pharmacol. 8:1997;383-388.
186. Nisell M., Nomikos G.G., Hertel P., Panagis G., Svensson T.H. Condition-independent sensitization of locomotor stimulation and mesocortical dopamine release following chronic nicotine treatment in the rat. Synapse. 22:1996;369-381.
187. Nisell M., Nomikos G.G., Chergui K., Grillner P., Svensson T.H. Chronic nicotine enhances basal and nicotine-induced for immunoreactivity preferentially in the medial prefrontal cortex of the rat. Neuropsychopharmacology. 17:1997;151-161.
188. Nishijima K., Kashiwa A., Hashimoto A., Iwama H., Umino A., Nishikawa T. Differential effects of phencyclidine and methamphetamine on dopamine metabolism in rat frontal cortex and striatum as revealed by in vivo dialysis. Synapse. 22:1996;304-312.
189. O'Donnell P., Grace A.A. Synaptic interaction among excitatory afferents to nucleus accumbens neurons. Hippocampal gating of prefrontal cortical input J Neurosci. 15:1995;3622-3639.
190. O'Donnell P., Grace A.A. Hippocampal modulation of cortical throughput in the nucleus accumbens. Modulation by dopamine Biol Psychiat. 39:1996;632.
191. O'Donnell P., Grace A.A. Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptoms clusters. Schizophr Bull. 24:1998;267-283.
192. Ogura H., Aigner T.G. MK-801 impairs recognition memory in rhesus monkeys. Comparison with cholinergic drugs J Pharmacol Exp Ther. 266:1993;60-64.
193. 1 receptors in schizophrenia revealed by PET. Nature. 385:1997;634-636.
194. Olincy A., Ross R.G., Young D.A., Roath M., Freedman R. Improvements in smooth pursuit eye movements after cigarette smoking in schizophrenic patients. Neuropsychopharmacology. 18:1998;175-185.
195. Olney J.W., Labruyere J., Price M.T. Pathological changes in cerebrocortical neurons by phencyclidine and related drugs. Science. 244:1989;1360-1362.
196. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., Sesma M.A. NMDA receptor antagonist neurotoxicity. Mechanism and prevention Science. 254:1991;1515-1518.
197. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiat. 52:1995;998-1007.
198. Pallares M.A., Nadal R.A., Silvestre J.S., Ferre N.S. Effects of ketamine, a noncompetitive NMDA receptor antagonist, on the acquisition of the lever-press response in rats. Physiol Behav. 57:1995;389-392.
199. Park S., Holzman P.S. Schizophrenics show spatial working memory deficits. Arch Gen Psychiat. 49:1992;975-982.
200. Pearlson G.D. Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. Johns Hopkins Med J. 148:1981;25-33.
201. Pehek E.A., Meltzer H.Y., Yamamoto B.K. The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux. Eur J Pharmacol. 240:1993;107-109.
202. Perry T.L. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci Lett. 28:1982;81-85.
203. Petrides M. Specialized systems for the processing of mnemonic information within the primate frontal cortex. Phil Trans R Soc Lond B. 352:1996;1455-1462.
204. Petrides M., Milner B. Deficits on self-ordered tasks after frontal- and temporal-lobe lesions in man. Neuropsychologia. 20:1982;249-262.
205. Post R.M., Weiss S.R., Pert A. Cocaine-induced behavioral sensitization and kindling. Implications for the emergence of pscyhopathology and seizures Ann NY Acad Sci. 53:1988;292-308.
206. Pycock C.J., Carter C.K., Kerwin R.W. Effect of 6-hydroxydopamine lesioning of medial prefrontal cortex on neurotransmitter systems in subcortical sites in the rat. J Neurochem. 34:1980;91-99.
207. Qin Z.H., Zhang S.P., Weiss B. Dopaminergic and glutamatergic blocking drugs differentially regulate glutamic acid decarboxylase mRNA in mouse brain. Mol Brain Res. 21:1994;293-302.
208. Rainey J.M. Jr., Crowder M.K. Phencyclidine or ketamine. JAMA. 230:1974;824.
209. Rainey J.M. Jr., Crowder M.K. Prolonged psychosis attributed to phencyclidine. Report of three cases Am J Psychiat. 132:1975;1076-1078.
210. Robbins T.W. The case for frontostriatal dysfunction in schizophrenia. Schizophr Bull. 16:1990;391-402.
211. Robbins T.W. Dissociating executive functions of the prefrontal cortex. Phil Trans R Soc Lond B. 351:1996;1463-1471.
212. Roberts A.C., DeSalvia M.A., Wilkinson L.S., Collins P., Muir J.L., Eueri H.B.J., Robbins T.W. 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test. Possible interactions with subcortical dopamine J Neurosci. 14:1994;2531-2544.
213. Robinson E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration. A review and evaluation of animal models of amphetamine psychosis Brain Res. 396:1986;157-198.
214. 1-receptor agonist. Eur J Pharmacol. 307:1996;27-31.
215. Sams-Dodd F. Automation of the social interaction task by a video-tracking system. Behavioral effects of repeated phencyclidine treatment J Neurosci Meth. 59:1995;157-167.
216. Sams-Dodd F. Phencyclidine-induced stereotyped behavior and social isolation in rats. A possible animal model of schizophrenia Behav Pharmacol. 7:1996;3-23.
217. 1 dopamine receptors in prefrontal cortex. Involvement in working memory science. 251:1991;947-950.
218. Scalzo F.M., Holson R.R. The ontogeny of behavioral sensitization to phencyclidine. Neurotoxicol Teratol. 14:1992;7-14.
219. Schlemmer R.F., Davis J.M. A comparison of three psychotomimetic-induced models of psychosis in nonhuman primate social colonies. Prog Clin Biol Res. 131:1983;33-78.
220. Schmidt C.J., Fadayel G.M. The selective 5-HT2a receptor antagonist, MDL100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol. 273:1995;273-279.
221. Schneider J.S., Kovelowski C.J. Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys Brain Res. 519:1990;122-128.
222. 4. Neuropsychopharmacology 7:261-284.
223. Seeman P., Van Tol H.H.M. Dopamine receptor pharmacology. TIPS. 15:1994;264-270.
224. Selemon L.D., Rajkowska G., Goldman-Rakic P.S. Abnormally high neuronal density in two widespread areas of the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiat. 52:1995;805-818.
225. Shepard P.D., Connelly S.T., Lehmann H., Grobaski K.C. Effects of the enantiomers of (±)HA966 on dopamine neurons. An electrophysiological study of a chiral molecule Eur J Pharmacol. 285:1996;79-88.
226. Snyder S.H. Phencyclidine. Nature. 285:1980;355-356.
227. Snyder S.H. Psychotogenic drugs as models of schizophrenia. Neuropsychopharmacology. 1:1988;197-199.
228. Steinpreis R.E., Salamone J.D. The role of nucleus accumbens dopamine in the neurochemical and behavioral effects of PCP. a microdialysis and behavioral study Brain Res. 612:1993;263-270.
229. Steinpreis R.E., Sokolowski J.D., Papanikolaou A., Salamone J.D. The effects of haloperidol and clozapine on PCP- and amphetamine-induced suppression of social behavior in the rat. Pharmacol Biochem Behav. 47:1994;579-585.
230. Steinpreis R.E. The behavioral and neurochemical effects of phencyclidine in humans and animals. Some implications for modeling psychosis. Behav Brain Res. 74:1996;45-55.
231. Stevens L., Shapiro M., White N.M. Effects of NMDA receptor blockade on behaviors differentially affected by fimbria/fornix and amygldala lesions. Psychobiol. 25:1997;109-117.
232. Swerdlow N.R., Bakshi V.P., Geyer M.A. Seroquel restores sensorimotor gating in phencylidine-treated rats. J Pharmacol Exp Ther. 279:1996;1290-1299.
233. Tamminga C.A. Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol. 12:1998;21-36.
234. Tamminga C.A., Schaffer M.H., Smith R.C., Davis J.M. Schizophrenic symptoms improve with apomorphine. Science. 200:1978;567-568.
235. Tamminga C.A., Gotta M.D., Thaker G.K., Alphs L.D., Foster N.L. Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine. Arch Gen Psychiat. 43:1986;398-402.
236. Tandon R., Greden J.F. Cholinergic hyperactivity and negative schizophrenic symptoms. Arch Gen Psychiat. 46:1989;745-753.
237. Tang A.H., Franklin S.R. Acquisition of brightness discrimination in the rat is impaired by opiates with psychotomimetic properties. Pharmacol Biochem Behav. 18:1983;873-877.
238. Tang A.H., Ho P.M. Both competitive and noncompetitive antagonists of N-methyl-D-aspartic acid disrupt brightness discrimination in rats. Eur J Pharmacol. 151:1988;143-146.
239. Taylor J.R., Elsworth J.D., Roth R.H., Sladek J.R., Redmond Jr D.E. Cognitive and motor deficits in the acquisition of an object retrieval/detour task in MPTP-treated monkeys. Brain. 113:1990;617-637. a.
240. Taylor J.R., Roth R.H., Sladek J.R., Redmond D.E. Jr. Cognitive and motor deficits in the performance of an object retrieval/detour task with barrier in monkeys treated with MPTP. Long-term performance and effect of transparency of the barrier Behav Neurosci. 104:1990;564-576. b.
241. 2 and GluR-1 glutamate receptor mRNAs in the rat brain after treatment with phencyclidine. Acta Med Okayama. 49:1995;61-68.
242. Toru M., Kurumaji A., Ishimaru M. Excitatory amino acids. Implications for psychiatric disorders research Life Sci. 55:1994;1683-1699.
243. Tricklebank M.D., Singh L., Oles R.H., Preston C., Iverson S.D. The behavioral effects of MK801. A comparison with antagonists activing noncompetitively and competitively at the NMDA receptor Eur J Pharmacol. 167:1989;127-135.
244. Verin M., Partiot A., Pillon B., Malapani C., Agid Y., Dubois B. Delayed response tasks and prefrontal lesions in man - Evidence for self-generated patterns of behavior with poor environmental modulation. Neuropsychologia. 31:1993;1379-1396.
245. Verma A., Moghaddam B. The role of excitatory amino acids in prefrontal cortex function as assessed by spatial delayed alternation performance in rats. Modulation by dopamine J Neurosci. 16:1996;373-379.
246. 18F]fluorodeoxyglucose. Eur Neuropsychopharmacol. 7:1997;9-24.
247. Wang C, Showalter VM, Johnson KM (1998): Chronic phencyclidine treatment produces a selective upregulation of the NMDAR1 receptor subunit mRNA in rat forebrain. Soc Neurosci Abstr 24:1970.
248. Wang R.Y., Liang X. M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. Neuropsychopharmacology. 19:1998;74-85.
249. Watanabe M., Kodama T., Hikosaka K. Increase in extracellular dopamine in primate prefrontal cortex during a working memory task. J Neurophysiol. 78:1997;2795-2798.
250. Weinberger D.R., Berman K.F., Zec R.F. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence Arch Gen Psychiat. 43:1986;114-125.
251. Weinberger D.R., Berman K.F., Illowsky B.P. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism Arch Gen Psychiat. 45:1988;609-615.
252. Weinberger D.R., Berman K.F. Prefrontal function in schizophrenia. Confounds and controversies Phil Tran R Soc Lond B. 351:1996;1495-1503.
253. White I.M., Flory G.S., Hooper K.C., Speciale J., Banks D.A., Rebec G.V. Phencyclidine-induced increases in striatal neuron firing in behaving rats. Reversal by haloperidol and clozapine J Neural Trans [Gen Sect]. 102:1995;99-112.
254. Wolf M.E., Khansa M.R. Repeated administration to MK-801 produces sensitization to its own locomotor stimulant effects but blocks sensitization to amphetamine. Brain Res. 562:1991;164-168.
255. Woo T.U., Whitehead R.E., Melchitzky D.S., Lewis D.A. A subclass of prefrontal GABA axon terminals are selectively altered in schizophrenia. Proc Natl Acad Sci USA. 95:1998;5341-5346.
256. Wozniak D.F., Brosnon-Watters G., Nardi A., McEwen M., Corso T.D., Olney J.W., Fix A.S. MK-801 neurotoxicity in male mice. Histologic effects and chronic impairments in spatial learning Brain Res. 707:1996;165-179.
257. Wu J.C., Buchsbaum M.S., Bunney Jr W. Positron emission tomography study of phencyclidine users as a possible drug model of schizophrenia. Japan J Psychopharmacol. 11:1991;47-48.
258. Xu X., Domino E.F. Phencyclidine-induced behavioral sensitization. Pharmacol Biochem Behav. 47:1994;603-608.
259. Yonezawa Y., Kuroki T., Kawahara T., Tashiro N., Uchimura H. Involvement of γ-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex. Eur J Pharmacol. 341:1998;45-56.
260. Youngren K.D., Moghaddam B., Bunney B.S., Roth R.H. Preferential activation of dopamine overflow in prefrontal cortex produced by chronic clozapine treatment. Neurosci Lett. 165:1994;41-44.
261. Youngren K.D., Inglis F.M., Pivirotto P.J., Jedema H.P., Bradberry C.W., Goldman-Rakic P.S., Roth R.H., Moghaddam B. Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the canidate nucleus. Neuropsychopharmacology. in press:1998.
262. Ziedonis D.M., George T.P. Schizophrenia and nicotine use. Report of a pilot smoking cessation program and review of neurobiological and clinical issues Schizophr Bull. 23:1997;247-254.